Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.

NCT06061536 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV

Interventions

DRUG: Lipovirtide 10mg
DRUG: Lipovirtide 40mg
DRUG: Lipovirtide 60mg
DRUG: DTG

Sponsor

Shanxi Kangbao Biological Product Co., Ltd.

Collaborators

[object Object]